Neurology · AntidepressantRegulatory Approvalregulatorymid-term

FDA Approves Doxepin Hydrochloride Application by Sun Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 12:33:00 PM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Doxepin Hydrochloride by Sun Pharma is significant as it introduces a new competitor in the antidepressant market. This could shift market dynamics and necessitate strategic responses from other companies in the sector. Regulatory context from FDA (FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and consider strategies for differentiation. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Neurology · Antidepressant, 8 regulatory and 5 competitive items passed relevance filtering for Sun Pharma.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves Fingolimod Hydrochloride Application by Alembic. This approval may enhance Sun Pharma's portfolio in the antidepressant market, potentially increasing competition with existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL) (FDA). Entity match (doxepin hydrochloride); Regulatory pathway relevance (nda). This approval indicates compliance with FDA standards, which may set a precedent for future applications in similar therapeutic areas.

Key Risks

Elevated medium regulatory exposure for Sun Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval may lead to increased competition, potentially impacting market share for existing antidepressant therapies and influencing pricing strategies.
Upside for Sun Pharma may improve if Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market dynamics and consider strategies for differentiation.

What Would Change This Assessment

This becomes more urgent if Monitor market uptake and any subsequent competitive responses from other antidepressant manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (doxepin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PITOLISANT HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Fingolimod Hydrochloride Application by Alembic
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA grants priority review for NUPLAZID supplemental application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment

A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sun Pharma
Doxepin Hydrochloride

Commercial impact

medium

The approval may lead to increased competition, potentially impacting market share for existing antidepressant therapies and influencing pricing strategies.

Regulatory impact

medium

This approval indicates compliance with FDA standards, which may set a precedent for future applications in similar therapeutic areas.

What to watch

Monitor market uptake and any subsequent competitive responses from other antidepressant manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.